Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study.

Lippman SA, Mooney AC, Puren A, Hunt G, Grignon JS, Prach LM, Gilmore HJ, Truong HM, Barnhart S, Liegler T.

BMC Infect Dis. 2020 Mar 26;20(1):248. doi: 10.1186/s12879-020-4933-z.

2.

Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.

Lee SA, Telwatte S, Hatano H, Kashuba ADM, Cottrell ML, Hoh R, Liegler TJ, Stephenson S, Somsouk M, Hunt PW, Deeks SG, Yukl S, Savic RM.

J Acquir Immune Defic Syndr. 2020 Apr 15;83(5):530-537. doi: 10.1097/QAI.0000000000002287.

PMID:
32168200
3.

High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies.

Horsburgh BA, Lee E, Hiener B, Eden JS, Schlub TE, von Stockenstrom S, Odevall L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek DC, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S.

AIDS. 2020 Apr 1;34(5):659-668. doi: 10.1097/QAD.0000000000002465.

PMID:
31913161
4.

Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.

Lee E, von Stockenstrom S, Morcilla V, Odevall L, Hiener B, Shao W, Hartogensis W, Bacchetti P, Milush J, Liegler T, Sinclair E, Hatano H, Hoh R, Somsouk M, Hunt P, Boritz E, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S.

J Virol. 2020 Jan 17;94(3). pii: e01270-19. doi: 10.1128/JVI.01270-19. Print 2020 Jan 17.

5.

Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy.

Lee E, Bacchetti P, Milush J, Shao W, Boritz E, Douek D, Fromentin R, Liegler T, Hoh R, Deeks SG, Hecht FM, Chomont N, Palmer S.

Front Microbiol. 2019 Sep 26;10:2214. doi: 10.3389/fmicb.2019.02214. eCollection 2019.

6.

How are transgender women acquiring HIV? Insights from phylogenetic transmission clusters in San Francisco.

Truong HM, O'Keefe KJ, Pipkin S, Liegler T, Scheer S, Wilson E, McFarland W.

AIDS. 2019 Nov 1;33(13):2073-2079. doi: 10.1097/QAD.0000000000002318.

PMID:
31335804
7.

HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.

Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, Kabami J, Sang N, Liegler T, Chamie G, Camlin CS, Jain V, Kadede K, Atukunda M, Ruel T, Shade SB, Ssemmondo E, Byonanebye DM, Mwangwa F, Owaraganise A, Olilo W, Black D, Snyman K, Burger R, Getahun M, Achando J, Awuonda B, Nakato H, Kironde J, Okiror S, Thirumurthy H, Koss C, Brown L, Marquez C, Schwab J, Lavoy G, Plenty A, Mugoma Wafula E, Omanya P, Chen YH, Rooney JF, Bacon M, van der Laan M, Cohen CR, Bukusi E, Kamya MR, Petersen M.

N Engl J Med. 2019 Jul 18;381(3):219-229. doi: 10.1056/NEJMoa1809866.

8.

Improvements in the South African HIV care cascade: findings on 90-90-90 targets from successive population-representative surveys in North West Province.

Lippman SA, El Ayadi AM, Grignon JS, Puren A, Liegler T, Venter WDF, Ratlhagana MJ, Morris JL, Naidoo E, Agnew E, Barnhart S, Shade SB.

J Int AIDS Soc. 2019 Jun;22(6):e25295. doi: 10.1002/jia2.25295.

9.

Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015.

Truong HM, Pipkin S, Grant RM, Liegler T, O'Keefe KJ, Scheer S.

PLoS One. 2019 Mar 14;14(3):e0213167. doi: 10.1371/journal.pone.0213167. eCollection 2019.

10.

Beyond Social Desirability Bias: Investigating Inconsistencies in Self-Reported HIV Testing and Treatment Behaviors Among HIV-Positive Adults in North West Province, South Africa.

Mooney AC, Campbell CK, Ratlhagana MJ, Grignon JS, Mazibuko S, Agnew E, Gilmore H, Barnhart S, Puren A, Shade SB, Liegler T, Lippman SA.

AIDS Behav. 2018 Jul;22(7):2368-2379. doi: 10.1007/s10461-018-2155-9.

PMID:
29779162
11.

False-positive HIV diagnoses: lessons from Ugandan and Russian research cohorts.

Coleman SM, Gnatienko N, Lloyd-Travaglini CA, Winter MR, Bridden C, Blokhina E, Lioznov D, Adong J, Samet JH, Liegler T, Hahn JA.

HIV Clin Trials. 2018 Feb;19(1):15-22. doi: 10.1080/15284336.2018.1429846. Epub 2018 Jan 31.

12.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

13.

Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants.

Hiener B, Horsburgh BA, Eden JS, Barton K, Schlub TE, Lee E, von Stockenstrom S, Odevall L, Milush JM, Liegler T, Sinclair E, Hoh R, Boritz EA, Douek D, Fromentin R, Chomont N, Deeks SG, Hecht FM, Palmer S.

Cell Rep. 2017 Oct 17;21(3):813-822. doi: 10.1016/j.celrep.2017.09.081.

14.

A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals.

Cockerham LR, Yukl SA, Harvill K, Somsouk M, Joshi SK, Sinclair E, Liegler T, Hoh R, Lyons S, Hunt PW, Rupert A, Sereti I, Morcock DR, Rhodes A, Emson C, Hellerstein MK, Estes JD, Lewin S, Deeks SG, Hatano H.

Pathog Immun. 2017;2(3):310-334. doi: 10.20411/pai.v2i3.207. Epub 2017 Aug 2.

15.

Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa.

Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, Kabami J, Owaraganise A, Liegler T, Mwangwa F, Kadede K, Jain V, Plenty A, Brown L, Lavoy G, Schwab J, Black D, van der Laan M, Bukusi EA, Cohen CR, Clark TD, Charlebois E, Kamya M, Havlir D.

JAMA. 2017 Jun 6;317(21):2196-2206. doi: 10.1001/jama.2017.5705.

16.

Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis.

Jain V, Petersen ML, Liegler T, Byonanebye DM, Kwarisiima D, Chamie G, Sang N, Black D, Clark TD, Ladai A, Plenty A, Kabami J, Ssemmondo E, Bukusi EA, Cohen CR, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration.

Lancet HIV. 2017 Mar;4(3):e122-e133. doi: 10.1016/S2352-3018(16)30220-X. Epub 2016 Dec 16. Erratum in: Lancet HIV. 2017 Mar;4(3):e102.

17.

Correction: Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes.

Willberg CB, Garrison KE, Jones RB, Meiklejohn DA, Spotts G, Liegler TJ, Ostrowski MA, Karlsson AC, Hecht FM, Nixon DF.

PLoS One. 2016 Jul 25;11(7):e0160293. doi: 10.1371/journal.pone.0160293. eCollection 2016.

18.

Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.

Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T, Mayer KH, Patel R, Almonte A, Chan PA.

PLoS One. 2016 Jun 22;11(6):e0157742. doi: 10.1371/journal.pone.0157742. eCollection 2016.

19.

Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya.

Kadede K, Ruel T, Kabami J, Ssemmondo E, Sang N, Kwarisiima D, Bukusi E, Cohen CR, Liegler T, Clark TD, Charlebois ED, Petersen ML, Kamya MR, Havlir DV, Chamie G; SEARCH team.

AIDS. 2016 Sep 10;30(14):2121-6. doi: 10.1097/QAD.0000000000001180.

20.

Attrition and Opportunities Along the HIV Care Continuum: Findings From a Population-Based Sample, North West Province, South Africa.

Lippman SA, Shade SB, El Ayadi AM, Gilvydis JM, Grignon JS, Liegler T, Morris J, Naidoo E, Prach LM, Puren A, Barnhart S.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):91-9. doi: 10.1097/QAI.0000000000001026.

21.

A hybrid mobile approach for population-wide HIV testing in rural east Africa: an observational study.

Chamie G, Clark TD, Kabami J, Kadede K, Ssemmondo E, Steinfeld R, Lavoy G, Kwarisiima D, Sang N, Jain V, Thirumurthy H, Liegler T, Balzer LB, Petersen ML, Cohen CR, Bukusi EA, Kamya MR, Havlir DV, Charlebois ED.

Lancet HIV. 2016 Mar;3(3):e111-9. doi: 10.1016/S2352-3018(15)00251-9. Epub 2016 Jan 26.

22.

Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection.

Gega A, Kozal MJ, Chiarella J, Lee E, Peterson J, Hecht FM, Liegler T, St John EP, Simen BB, Price RW, Spudich SS.

J Virus Erad. 2015;1(4):264-268.

23.

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.

Chew GM, Fujita T, Webb GM, Burwitz BJ, Wu HL, Reed JS, Hammond KB, Clayton KL, Ishii N, Abdel-Mohsen M, Liegler T, Mitchell BI, Hecht FM, Ostrowski M, Shikuma CM, Hansen SG, Maurer M, Korman AJ, Deeks SG, Sacha JB, Ndhlovu LC.

PLoS Pathog. 2016 Jan 7;12(1):e1005349. doi: 10.1371/journal.ppat.1005349. eCollection 2016 Jan.

24.

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA.

JAMA Intern Med. 2016 Jan;176(1):75-84. doi: 10.1001/jamainternmed.2015.4683.

25.

Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco.

Truong HM, Pipkin S, OʼKeefe KJ, Louie B, Liegler T, McFarland W, Grant RM, Bernstein K, Scheer S.

J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):606-9. doi: 10.1097/QAI.0000000000000681.

26.

Newly Exerted T Cell Pressures on Mutated Epitopes following Transmission Help Maintain Consensus HIV-1 Sequences.

Eriksson EM, Liegler T, Keh CE, Karlsson AC, Holditch SJ, Pilcher CD, Loeb L, Nixon DF, Hecht FM.

PLoS One. 2015 Apr 28;10(4):e0120787. doi: 10.1371/journal.pone.0120787. eCollection 2014.

27.

Select host restriction factors are associated with HIV persistence during antiretroviral therapy.

Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, Pilcher CD, Hecht FM, Liegler T, Richman DD, Deeks SG, Pillai SK.

AIDS. 2015 Feb 20;29(4):411-20. doi: 10.1097/QAD.0000000000000572.

28.

Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis.

Grant RM, Liegler T.

J Infect Dis. 2015 Apr 15;211(8):1202-4. doi: 10.1093/infdis/jiu678. Epub 2015 Jan 13. No abstract available.

29.

The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

Somsouk M, Dunham RM, Cohen M, Albright R, Abdel-Mohsen M, Liegler T, Lifson J, Piatak M, Gorelick R, Huang Y, Wu Y, Hsue PY, Martin JN, Deeks SG, McCune JM, Hunt PW.

PLoS One. 2014 Dec 29;9(12):e116306. doi: 10.1371/journal.pone.0116306. eCollection 2014.

30.

Design and implementation of an external quality assessment program for HIV viral load measurements using dried blood spots.

Prach LM, Puren A, Lippman SA, Carmona S, Stephenson S, Cutler E, Barnhart S, Liegler T.

J Clin Microbiol. 2015 Mar;53(3):964-6. doi: 10.1128/JCM.02698-14. Epub 2014 Dec 17.

31.

Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.

Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV.

AIDS. 2015 Jan 28;29(3):331-7.

PMID:
25503265
32.

Role of microRNA modulation in the interferon-α/ribavirin suppression of HIV-1 in vivo.

Abdel-Mohsen M, Deng X, Danesh A, Liegler T, Jacobs ES, Rauch A, Ledergerber B, Norris PJ, Günthard HF, Wong JK, Pillai SK.

PLoS One. 2014 Oct 2;9(10):e109220. doi: 10.1371/journal.pone.0109220. eCollection 2014.

33.

Decreased HIV type 1 transcription in CCR5-Δ32 heterozygotes during suppressive antiretroviral therapy.

Wang C, Abdel-Mohsen M, Strain MC, Lada SM, Yukl S, Cockerham LR, Pilcher CD, Hecht FM, Sinclair E, Liegler T, Richman DD, Deeks SG, Pillai SK.

J Infect Dis. 2014 Dec 1;210(11):1838-43. doi: 10.1093/infdis/jiu338. Epub 2014 Jun 16.

34.

HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.

Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM; iPrEx Study Team.

J Infect Dis. 2014 Oct 15;210(8):1217-27. doi: 10.1093/infdis/jiu233. Epub 2014 Apr 16.

35.

Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo.

Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel-D, Rauch A, Ledergerber B, Deeks SG, Günthard HF, Wong JK, Pillai SK.

J Virol. 2014 Jan;88(1):763-7. doi: 10.1128/JVI.02687-13. Epub 2013 Oct 23.

36.

Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access.

Jain V, Byonanebye DM, Liegler T, Kwarisiima D, Chamie G, Kabami J, Petersen ML, Balzer LB, Clark TD, Black D, Thirumurthy H, Geng EH, Charlebois ED, Amanyire G, Kamya MR, Havlir DV; SEARCH Collaboration.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):327-32. doi: 10.1097/QAI.0000000000000021.

37.

Expression profile of host restriction factors in HIV-1 elite controllers.

Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, Salama MS, Ghanem Hel-D, Hoh R, Wong JK, David M, Nixon DF, Deeks SG, Pillai SK.

Retrovirology. 2013 Oct 16;10:106. doi: 10.1186/1742-4690-10-106.

38.

Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.

Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, Abdel-Mohsen M, Liegler T, Harvill K, Hoh R, Palmer S, Bacchetti P, Hunt PW, Martin JN, McCune JM, Tracy RP, Busch MP, O'Doherty U, Shacklett BL, Wong JK, Deeks SG.

PLoS Pathog. 2013;9(10):e1003691. doi: 10.1371/journal.ppat.1003691. Epub 2013 Oct 10.

39.

Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study.

Huchko MJ, Woo VG, Liegler T, Leslie H, Smith-McCune K, Sawaya GF, Bukusi EA, Cohen CR.

BJOG. 2013 Sep;120(10):1233-9. doi: 10.1111/1471-0528.12258. Epub 2013 May 7.

40.

Association of cervical biopsy with HIV type 1 genital shedding among women on highly active antiretroviral therapy.

Woo VG, Liegler T, Cohen CR, Sawaya GF, Smith-McCune K, Bukusi EA, Huchko MJ.

AIDS Res Hum Retroviruses. 2013 Jul;29(7):1000-5. doi: 10.1089/AID.2012.0341. Epub 2013 May 15.

41.

Is there an association between HIV-1 genital shedding and cervical intraepithelial neoplasia 2/3 among women on antiretroviral therapy?

Huchko MJ, Woo V, Liegler T, Leddy A, Smith-McCune K, Sawaya GF, Bukusi EA, Cohen CR.

J Low Genit Tract Dis. 2013 Jul;17(3):354-60. doi: 10.1097/LGT.0b013e3182712286.

42.

Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.

Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV; SEARCH Collaboration.

Clin Infect Dis. 2013 Feb;56(4):598-605. doi: 10.1093/cid/cis881. Epub 2012 Dec 12. Erratum in: Clin Infect Dis. 2014 Aug 1;59(3):463.

43.

Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion.

Perez CL, Milush JM, Buggert M, Eriksson EM, Larsen MV, Liegler T, Hartogensis W, Bacchetti P, Lund O, Hecht FM, Nixon DF, Karlsson AC.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):602-12. doi: 10.1089/AID.2012.0171. Epub 2013 Jan 8.

44.

The cerebrospinal fluid proteome in HIV infection: change associated with disease severity.

Angel TE, Jacobs JM, Spudich SS, Gritsenko MA, Fuchs D, Liegler T, Zetterberg H, Camp DG 2nd, Price RW, Smith RD.

Clin Proteomics. 2012 Mar 20;9(1):3. doi: 10.1186/1559-0275-9-3.

45.

Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds.

Do T, Duncan J, Butcher A, Liegler T.

J Clin Virol. 2011 Dec;52 Suppl 1:S83-9. doi: 10.1016/j.jcv.2011.09.022. Epub 2011 Oct 12.

PMID:
21995930
46.

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW.

J Infect Dis. 2011 Sep 1;204(5):753-60. doi: 10.1093/infdis/jir387.

47.

Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK.

J Virol Methods. 2011 Aug;175(2):261-5. doi: 10.1016/j.jviromet.2011.04.015. Epub 2011 Apr 22.

48.

Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant RM, Cortes R, Deeks SG, Hecht FM.

J Infect Dis. 2011 Apr 15;203(8):1174-81. doi: 10.1093/infdis/jiq167.

49.

Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009.

Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM.

PLoS One. 2010 Dec 10;5(12):e15510. doi: 10.1371/journal.pone.0015510.

50.

APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection.

Gourraud PA, Karaouni A, Woo JM, Schmidt T, Oksenberg JR, Hecht FM, Liegler TJ, Barbour JD.

Hum Immunol. 2011 Mar;72(3):207-12. doi: 10.1016/j.humimm.2010.12.008. Epub 2010 Dec 15.

Supplemental Content

Loading ...
Support Center